# A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

> **NCT01470313** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 28 (actual)

## Conditions studied

- Cutaneous Lupus Erythematosus

## Interventions

- **DRUG:** PD-0360324
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01470313
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2014-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470313, "A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01470313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*